HomeCompareLFSC vs PFE

LFSC vs PFE: Dividend Comparison 2026

LFSC yields 5.73% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $20.4K in total portfolio value· pulled ahead in Year 9
10 years
LFSC
LFSC
● Live price
5.73%
Share price
$34.92
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.2K
Annual income
$825.53
Full LFSC calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — LFSC vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLFSCPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LFSC + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LFSC pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LFSC
Annual income on $10K today (after 15% tax)
$486.90/yr
After 10yr DRIP, annual income (after tax)
$701.70/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,618.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LFSC + PFE for your $10,000?

LFSC: 50%PFE: 50%
100% PFE50/50100% LFSC
Portfolio after 10yr
$39.4K
Annual income
$13,542.13/yr
Blended yield
34.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

LFSC
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LFSC buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLFSCPFE
Forward yield5.73%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$29.2K$49.6K
Annual income after 10y$825.53$26,258.71
Total dividends collected$7.0K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LFSC vs PFE ($10,000, DRIP)

YearLFSC PortfolioLFSC Income/yrPFE PortfolioPFE Income/yrGap
1$11,273$572.82$9,153$693.39+$2.1KLFSC
2$12,665$603.49$8,593$849.25+$4.1KLFSC
3$14,186$633.68$8,336$1,066.78+$5.8KLFSC
4$15,842$663.31$8,437$1,384.80+$7.4KLFSC
5$17,643$692.30$9,013$1,875.40+$8.6KLFSC
6$19,599$720.57$10,306$2,680.72+$9.3KLFSC
7$21,719$748.07$12,820$4,101.38+$8.9KLFSC
8$24,014$774.76$17,673$6,826.70+$6.3KLFSC
9← crossover$26,495$800.59$27,543$12,591.86$1.0KPFE
10$29,176$825.53$49,560$26,258.71$20.4KPFE

LFSC vs PFE: Complete Analysis 2026

LFSCStock

LFSC seeks to invest in innovative life sciences companies that are expected to create value and long-term growth. The actively managed fund relies on a specialized and experienced team to research complex life sciences companies. It invests in US equity securities identified to have growth potential that meet the criteria of technological advancement, market disruption, or artificial intelligence. The broad life science field includes biotechnology, pharmaceutical, medical diagnostics and devices, healthcare services and technologies, and synthetic biology. Stock selection employs an extensive 10-step research process that includes reviews of publicly available and third-party information, peer reviews, financial and valuation models, internal research, surveys, as well as interviews and contact with management, industry and medical professionals, supply chain, and collaboration within the investment team. The fund may invest up to 20% in foreign companies listed on a US exchange.

Full LFSC Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this LFSC vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LFSC vs SCHDLFSC vs JEPILFSC vs OLFSC vs KOLFSC vs MAINLFSC vs JNJLFSC vs MRKLFSC vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.